We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Efficacy of CRISPR/Cas9 mRNA Instantaneous Gene Editing Therapy to Treat Refractory Viral Keratitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04560790
Recruitment Status : Completed
First Posted : September 23, 2020
Last Update Posted : August 24, 2022
Eye & ENT Hospital of Fudan University
Information provided by (Responsible Party):
Shanghai BDgene Co., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : July 5, 2022
Actual Study Completion Date : July 5, 2022